RT Book, Section
A1 Minor, Deborah S.
A1 Harrell, T. Kristopher
A2 DiPiro, Joseph T.
A2 Talbert, Robert L.
A2 Yee, Gary C.
A2 Matzke, Gary R.
A2 Wells, Barbara G.
A2 Posey, L. Michael
SR Print(0)
ID 1167761712
T1 Headache Disorders
T2 Pharmacotherapy: A Pathophysiologic Approach, 10e
YR 2017
FD 2017
PB McGraw-Hill Education
PP New York, NY
SN 9781259587481
LK accesspharmacy.mhmedical.com/content.aspx?aid=1167761712
RD 2024/04/24
AB Content  UpdateNovember  15,  2019Newly  Approved  Medications  for  Migraines:  The  U.S.  FDA  approved  three  new  medications  with  novel  mechanism  of  action  for  migraine  prophylaxis.  The  calcitonin  gene-related  peptide  (CGRP)  antagonists,  erenumab  (Aimovig®),  fremanezumab  (Ajovy®),  and  galcanezumab  (Emgality®)  were  approved  in  2018  for  migraine  prophylaxis.The  CGRP  antagonist  therapies  were  approved  for  migraine  prophylaxis  in  adults  because  of  its  hypothesized  role  in  mediating  trigeminovascular  pain  transmission  and  vasodilation  activity  for  neurogenic  inflammation.  Although  these  medications  appear  effective,  more  data  are  needed  regarding  their  long-term  safety  as  well  as  use  in  special  populations.  All  three  therapies  are  available  in  the  United  States.